4 completed. 4 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Completed 4 |
Follow Post-inflammatory Hyperpigmentation: new trials by email Literature Review of Post-inflammatory Hyperpigmentation trials Research Report on Post-inflammatory Hyperpigmentation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation Topical Cetyl Tranexamate Mesylate - Hyperpigmentation, Post-inflammatory Hyperpigmentation | Not applicable | Completed | Integrative Skin Science and Research | 22 | 2023-11-06 | 2024-08-28 |
| Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots. Prototypes (816-v1 001) to (816-v1 050), Prototype (816-v1 051) to (816-v1 100), Prototypes (816-v1 101) to (816-v1 150) - Solar Lentigo, Senile Lentigo | Not applicable | Completed | Cryonove Pharma | 32 | 2023-04-17 | 2024-01-19 |
| Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Post-inflamamatory Hyperpigmentation (PIH). Prototype (814A-v1), Prototype (814B-v1), Prototype (814C-v1) - Post-inflammatory Hyperpigmentation | Not applicable | Completed | Cryonove Pharma | 12 | 2022-10-18 | 2023-06-26 |
| An In Vivo Model for Postinflammatory Hyperpigmentation Tricholoacetic Acid (TCA) - Post-inflammatory Hyperpigmentation | Not applicable | Completed | Henry Ford Health System | 30 | 2016-02-14 | 2022-03-02 |
Hyperpigmentation (4) · Acne Vulgaris (1) · Skin Diseases (1)
Pigmentation Disorders (4) · Skin and Connective Tissue Diseases (4) · Skin Diseases (3) · Acneiform Eruptions (1) · Sebaceous Gland Diseases (1)
Cryonove Pharma (2) · Henry Ford Health System (1) · Integrative Skin Science and Research (1)
South Africa (2) · United States (2)
Beverley Summers (1) · Iltefat Hamzavi, MD (1) · Raja Sivamani, MD MS AP (1)